ECSP088764A - Métodos para tratar trastornos cognitivos y otros afines - Google Patents

Métodos para tratar trastornos cognitivos y otros afines

Info

Publication number
ECSP088764A
ECSP088764A EC2008008764A ECSP088764A ECSP088764A EC SP088764 A ECSP088764 A EC SP088764A EC 2008008764 A EC2008008764 A EC 2008008764A EC SP088764 A ECSP088764 A EC SP088764A EC SP088764 A ECSP088764 A EC SP088764A
Authority
EC
Ecuador
Prior art keywords
methods
cognitive disorders
treat cognitive
disorders
treat
Prior art date
Application number
EC2008008764A
Other languages
English (en)
Inventor
Sharon Rosenzweig-Lipson
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of ECSP088764A publication Critical patent/ECSP088764A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Esta invención proporciona métodos y composiciones farmacéuticas para tratar trastornos cognitivos tales como trastornos de aprendizaje y ADD/ADHD, y otros trastornos.
EC2008008764A 2006-03-24 2008-09-23 Métodos para tratar trastornos cognitivos y otros afines ECSP088764A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78565406P 2006-03-24 2006-03-24
US85127806P 2006-10-12 2006-10-12

Publications (1)

Publication Number Publication Date
ECSP088764A true ECSP088764A (es) 2008-10-31

Family

ID=38235219

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008764A ECSP088764A (es) 2006-03-24 2008-09-23 Métodos para tratar trastornos cognitivos y otros afines

Country Status (18)

Country Link
US (1) US20070225278A1 (es)
EP (1) EP2015749A2 (es)
JP (1) JP2009531431A (es)
KR (1) KR20080105105A (es)
AR (1) AR060088A1 (es)
AU (1) AU2007229491A1 (es)
BR (1) BRPI0709146A2 (es)
CA (1) CA2644618A1 (es)
CL (1) CL2007000773A1 (es)
EC (1) ECSP088764A (es)
IL (1) IL193697A0 (es)
MX (1) MX2008012208A (es)
NO (1) NO20083751L (es)
PA (1) PA8720401A1 (es)
PE (1) PE20080126A1 (es)
RU (1) RU2008135115A (es)
TW (1) TW200806297A (es)
WO (1) WO2007111982A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200500317A (es) * 2004-11-05 2006-10-27 Proceso para preparar compuestos de quinolina y productos obtenidos de los mismos
PE20060939A1 (es) * 2004-11-05 2006-11-10 Wyeth Corp Metabolitos derivados de [1,4] diazepin[6,7,1-ij] quinolina y procedimiento de preparacion
AR051946A1 (es) * 2004-11-05 2007-02-21 Wyeth Corp Formulaciones de derivados de [1,4] diazepina [6,7,1-ij] quinolina
AR054849A1 (es) * 2005-07-26 2007-07-18 Wyeth Corp Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas
TW200734334A (en) * 2006-01-13 2007-09-16 Wyeth Corp Treatment of substance abuse
JP2009531435A (ja) * 2006-03-24 2009-09-03 ワイス うつ病の治療用の新規な治療組み合わせ
TW200806298A (en) * 2006-03-24 2008-02-01 Wyeth Corp Methods for modulating bladder function
BRPI0709163A2 (pt) * 2006-03-24 2011-06-28 Wyeth Corp tratamento da dor
CL2008002777A1 (es) * 2007-09-21 2010-01-22 Wyeth Corp Metodo de preparacion de compuestos diazepinoquinolinicos quirales por recristalizacion en un sistema de solvente ternario.

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3158619A (en) * 1962-06-14 1964-11-24 Searle & Co Certain sulfur-containing ortho-fused polycyclic pyrazole derivatives
US3235564A (en) * 1964-03-27 1966-02-15 Searle & Co Intermediates to certain sulfur-containing ortho-fused polycyclic pyrazole derivatives
US3335134A (en) * 1964-04-02 1967-08-08 Sandoz Ag Certain 3, 4-dihydrofluoreno[1, 9a, 9-e, f]1, 4-diazepin-3(2h)-ones
US3296252A (en) * 1964-04-02 1967-01-03 Sandoz Ag Tetracyclic diazepinone compounds
GB1120461A (en) * 1964-07-06 1968-07-17 Manuf Prod Pharma Derivatives of fluoreno-[1,9-ef]1,4-diazepine-1-oxide
US3417101A (en) * 1964-11-09 1968-12-17 American Home Prod Fused ring compounds
US3329676A (en) * 1964-11-09 1967-07-04 American Home Prod Fused 1, 4-diazepine ring systems
US3714149A (en) * 1969-11-03 1973-01-30 Upjohn Co Pyridobenzodiazepinones
US3914250A (en) * 1974-08-01 1975-10-21 American Home Prod 1,4-Diazepino{8 6,5,4-jk{9 carbazoles
US4880814A (en) * 1987-11-13 1989-11-14 Abbott Laboratories 7-cycloalkyl naphthyridines
GB8812636D0 (en) * 1988-05-27 1988-06-29 Glaxo Group Ltd Chemical compounds
US4997831A (en) * 1988-09-01 1991-03-05 Glaxo Group Limited Lactam derivatives
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5565483A (en) * 1995-06-07 1996-10-15 Bristol-Myers Squibb Company 3-substituted oxindole derivatives as potassium channel modulators
CA2195697A1 (en) * 1996-02-02 1997-08-03 Masahumi Kitano Novel substituted guanidine derivatives, process for production thereof, and pharmaceutical uses thereof
GB9711643D0 (en) * 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
US6031098A (en) * 1997-08-11 2000-02-29 California Institute Of Technology Detection and treatment of duplex polynucleotide damage
DE1073432T1 (de) * 1998-04-14 2002-02-07 Gen Hospital Corp Verwendung von glycinrezeptoragonisten und glycinaufnahmeinhibitoren zur behandlung neuropsychiatrischer beschwerden
CO5210925A1 (es) * 1998-11-17 2002-10-30 Novartis Ag Derivados de diamino nitroguanidina tetrasustituidos
US6503900B2 (en) * 2000-11-03 2003-01-07 Wyeth [1,4]diazepino [6,7,1-jk ]carbazoles and derivatives
AU2002227170A1 (en) * 2000-11-03 2002-05-15 Wyeth Cycloalkyl(b)(1,4)diazepino(6,7,1-hi)indoles and derivatives
AR031195A1 (es) * 2000-11-03 2003-09-10 Wyeth Corp Procedimiento para la preparacion de derivados de 1,2,3,4,8,9,10,10a-octahidro-7bh-ciclopenta (b) (1,4) diazepino (6,7,1) diazepino (6,7,1-hi) indol
AR031202A1 (es) * 2000-11-03 2003-09-10 Wyeth Corp Ciclopenta(b) (1,4)diazepino(6,7,1-hi) indoles y derivados
US6759405B2 (en) * 2000-11-03 2004-07-06 Wyeth Cycloocta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives
US6858604B2 (en) * 2000-11-03 2005-02-22 Wyeth Cyclohepta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives
AR031198A1 (es) * 2000-11-03 2003-09-10 Wyeth Corp Procedimiento para la preparacion de derivados de ciclopenta(b)diazepino(6,7,1)indol
RU2003121304A (ru) * 2000-12-20 2005-01-27 Бристол-Маерс Сквибб Компани (Us) Замещенные пиридоиндолы в качестве агонистов и антагонистов серотонина
US6849619B2 (en) * 2000-12-20 2005-02-01 Bristol-Myers Squibb Company Substituted pyridoindoles as serotonin agonists and antagonists
US20020183395A1 (en) * 2001-04-04 2002-12-05 Wyeth Methods for treating hyperactive gastric motility
MXPA04001202A (es) * 2001-08-06 2005-02-17 Pharmacia & Upjhon Company Ligandos tetraciclicos terapeuticamente utiles.
BR0213417A (pt) * 2001-10-18 2004-11-03 Upjohn Co Compostos e composições de tetraciclicazaindóis e indolinas tendo atividade de 5-ht e seus usos
TW200307540A (en) * 2002-04-25 2003-12-16 Wyeth Corp [1, 4]Diazocino[7, 8, 1-hi] indole derivatives as antipsychotic and antiobesity agents
TWI312781B (en) * 2002-04-25 2009-08-01 [1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
TW200307682A (en) * 2002-04-25 2003-12-16 Wyeth Corp 1,2,3,4,7,8-Hexahydro-6H-[1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
US20040235856A1 (en) * 2003-04-25 2004-11-25 Pfizer Inc Treatment of incontinence
PE20060939A1 (es) * 2004-11-05 2006-11-10 Wyeth Corp Metabolitos derivados de [1,4] diazepin[6,7,1-ij] quinolina y procedimiento de preparacion
AR051946A1 (es) * 2004-11-05 2007-02-21 Wyeth Corp Formulaciones de derivados de [1,4] diazepina [6,7,1-ij] quinolina
GT200500317A (es) * 2004-11-05 2006-10-27 Proceso para preparar compuestos de quinolina y productos obtenidos de los mismos
AR054849A1 (es) * 2005-07-26 2007-07-18 Wyeth Corp Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas
AR056695A1 (es) * 2005-10-17 2007-10-17 Wyeth Corp Tetrahidroquinolinas, su sintesis e intermediarios
TW200734334A (en) * 2006-01-13 2007-09-16 Wyeth Corp Treatment of substance abuse
BRPI0709129A2 (pt) * 2006-03-24 2011-06-28 Wyeth Corp combinações terapêuticas para o tratamento ou prevenção de transtornos psicóticos
JP2009531435A (ja) * 2006-03-24 2009-09-03 ワイス うつ病の治療用の新規な治療組み合わせ
BRPI0709163A2 (pt) * 2006-03-24 2011-06-28 Wyeth Corp tratamento da dor
CL2008002777A1 (es) * 2007-09-21 2010-01-22 Wyeth Corp Metodo de preparacion de compuestos diazepinoquinolinicos quirales por recristalizacion en un sistema de solvente ternario.

Also Published As

Publication number Publication date
PA8720401A1 (es) 2008-12-18
EP2015749A2 (en) 2009-01-21
WO2007111982A3 (en) 2007-11-15
CA2644618A1 (en) 2007-10-04
RU2008135115A (ru) 2010-04-27
JP2009531431A (ja) 2009-09-03
PE20080126A1 (es) 2008-04-07
CL2007000773A1 (es) 2008-01-25
NO20083751L (no) 2008-10-20
IL193697A0 (en) 2009-08-03
WO2007111982A2 (en) 2007-10-04
KR20080105105A (ko) 2008-12-03
US20070225278A1 (en) 2007-09-27
AR060088A1 (es) 2008-05-21
AU2007229491A1 (en) 2007-10-04
TW200806297A (en) 2008-02-01
BRPI0709146A2 (pt) 2011-06-28
MX2008012208A (es) 2008-10-02

Similar Documents

Publication Publication Date Title
ECSP088764A (es) Métodos para tratar trastornos cognitivos y otros afines
ECSP23004573A (es) Compuestos y composiciones como inhibidores de cinasa de proteina
ECSP22051489A (es) Compuestos inhibidores de metaloenzimas
BRPI0808775A2 (pt) compostos e composições como moduladores de atividade de gpr119
EA201001329A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
TN2010000122A1 (en) Compounds and compositions as modulators of gpr119 activity
BR112012008004A2 (pt) compostos e composições como moduladores da atividade de gpr119
CR20120202A (es) Métodos y composiciones para tratar cáncer
CR20110103A (es) Heteroarilos sustituidos
GT201300209A (es) Compuestos y composiciones como inhibidores de la trk
EA201001332A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
CR10208A (es) Inhibidores de quinasa basados en la hidantoina
BRPI0818732A2 (pt) Composições de análogo de prostaglandina e métodos para tratar condições relacionadas epiteliais.
CR11284A (es) Sulfonamidas como moduladores de trpm8
BRPI0817775A2 (pt) Métodos de tratar distúrbios urogenitais-neurológicos usando toxinas clostridiais modificadas
EA200901032A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
WO2012034116A3 (en) Small molecules as epigenetic modulators of lysine-specific demethylase 1 and methods of treating disorders
BRPI0908334A2 (pt) kit, composição, produto ou medicamento para tratar comprometimento cognitivo
EA201001330A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
BRPI0712607A8 (pt) métodos de tratamento de acidente vascular cerebral
UY30479A1 (es) Moduladores de benzofuro- y benzotienopirimidina del receptor de histamina h4
CL2011001427A1 (es) Compuestos derivados de 4-azetidinil-1-heteroaril-ciclohexanol; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como epoc, aterosclerosis, artritis reumatoide, entre otras.
BR112014000634A2 (pt) métodos para tratamento de incontinência associada com atividade sexual
WO2011014520A3 (en) Compounds and compositions as modulators of gpr119 activity
BRPI0821131A2 (pt) Método e composição para tratar uma condição mediada por receptor de serotonina